Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Market Reports
A matter of material choice
Dr Kevin Robinson recently caught up with DuPont’s Eric Schmohl, Global Marketing Manager for Tyvek Pharmaceutical Packaging, and Jean-François Teneul, Global Life Sciences Market Leader of Tyvek Protective Apparel, to discuss the importance of protecting both people and product during aseptic fill-&-finish processes
Meeting the global demand for high quality pharmaceutical packaging
Amidst a flurry of recent announcements at the recent DCAT Week in New York, Dr Kevin Robinson sat down with Dr Frank Heinricht, Chairman of the Management Board of SCHOTT AG, to discover how the company is addressing issues in the pharmaceutical value chain, from glass tubing to packaging and the application of artificial intelligence
Continuous manufacturing: making it real
Industry pioneers GEA, Siemens and Perceptive Engineering recently hosted the inaugural Reality of Continuous Pharmaceutical Manufacturing conference in Durham, UK, to examine the current status of going conti and present real-life applications to an international audience. Dr Kevin Robinson reports
Global serialisation: Russian track and trace readiness
Christoph Krähenbühl, Senior Director of Excellis Europe, explains the challenge that the new Russian traceability regulations present to the pharma industry and how all participants in the supply chain must properly prepare to ensure that they become compliant within this new environment
Backend, baffling and buzzing: blockchain
Marco Mohwinckel, healthcare executive and adviser, takes a closer look at the invisible backend technology that has been touted as a revolution
Digitalisation in specialty chemicals and pharmaceuticals
Paige Marie Morse, Industry Director, AspenTech talks to Dr Kevin Robinson about accelerating innovation and optimising the value chain with digital technologies
Supporting precision with precision
As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and meticulous support to ensure effective delivery to the patient
The economic advantages of continuous flow chemistry
Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
The modularisation of chemical API synthesis
The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
Rare diseases: understanding the patient journey
In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research
A new paradigm in vaccines and cancer treatments
Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more
Fuelling pharma’s innovation engines
Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations
Broad stripes, bright stars and a thriving pharmaceutical industry: part I
According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey
The hidden risk of contamination
Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL
A revolutionary method of liquid flow measurement
Pharmaceutical supplier opts for innovative hygienic flowmeter
Next-generation safety testing
In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Developments and the future of pharmaceutical packaging
With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered
Is the production of biologic drugs ready for an overhaul?
Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson
Leaders of transformation
Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development
Continuous manufacturing: the facts and the future
Many companies talk about continuous manufacturing (CM), but few speak with the experience of actually implementing a continuous process line. Dr Kevin Robinson spoke to GEA’s Richard Steiner to find out why
Looking back on 2018 and making predictions for 2019
As the global pharmaceutical industry transitions from the knowns of 2018 into the unknowns of 2019, Dr Kevin Robinson caught up with some of the key players in the market to assess the year that was and the 12 months to come in terms of upcoming trends and developments
Serialisation is not enough
A global technology leader in supply chain security, Systech’s revolutionary solution provides authentic, safe and connected products throughout the pharmaceutical supply chain. Dr Kevin Robinson recently caught up with CEO Ara Ohanian to find out more
Preparing PIs for post EU-FMD success
Ian Haynes of Excellis Europe explains how the company’s unique approach to enabling collaboration between parallel importers is helping to simplify the transition to serialisation post EU-FMD
Eliminating the time thieves
Comprehensive scientific process engineering (CSPE) cuts delivery times and accelerates the commissioning of pharmaceutical systems. Dr Kevin Robinson spoke to Optima Pharma’s Gerhard Breu to find out more
Previous
1
…
4
5
6
7
8
(current)
9
10
Next
Trending Articles
UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap?
Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
You need to be a subscriber to read this article.
Click here
to find out more.
Performance validation: HPAPI containment testing in a risk-based era
Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance
QInscribe unveils AI-powered medical writing to revolutionise regulatory submissions
New medical writing service provider QInscribe reduces the time to generate a draft clinical study report (CSR) by 90% with a generative AI solution
Peak identification by LC/MS: Automation versus analyst
High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
Recombinant versus synthetic peptide synthesis: the perks and drawbacks
Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin